Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNV17I
|
|||
| Drug Name |
LY3113593
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Anaemia [ICD-11: 3A90; ICD-10: D64.8] | Phase 2 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bone morphogenetic protein 6 (BMP6) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02604160) A Study of LY3113593 in Participants With Chronic Kidney Disease. U.S. National Institutes of Health. | |||
| REF 2 | Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol. 2019 May;85(5):935-948. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.